TrialOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Trial details
- Registry ID
- NCT04848506
- Phase
- Phase 2, Phase 3
Drug research
Aficamten (5 - 20 mg)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMNCT04848506 | Cytokinetics | Phase 2, Phase 3 | Enrolling by invitation | 2028-03Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |